autologous AML/dendritic cell fusion vaccine

{
  "id": "MLC-T-ONC-011323",
  "term": "autologous AML/dendritic cell fusion vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A therapeutic cell-based cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. The autologous AML/DC fusion vaccine is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. Upon re-administration, the autologous AML/DC fusion vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis.",
  "synonyms": [
    "autologous AML/DC fusion vaccine",
    "autologous DC/AML fusion vaccine",
    "DC/AML fusion cell vaccine",
    "autologous dendritic cell/AML fusion vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-aml-dendritic-cell-fusion-vaccine/"
}